Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein

Abstract

Purpose:

Myelin oligodendrocyte glycoprotein autoantibodies are associated with certain optic neuritis. Little data are known about the specificity of the initial ophthalmologic presentation.

Methods:

A monocentric retrospective study (2013–2017) of all patients diagnosed with myelin oligodendrocyte glycoprotein+ optic neuritis in a tertiary ophthalmologic unit was conducted. The primary objective was to define the clinical ophthalmologic description of the first episode. The secondary objective was to evaluate the evolution and final diagnosis.

Results:

A total of nine patients were included. There was no female predominance (sex ratio f/m = 0.8). At the first optic neuritis episode, the average age was 39.3 years (17–67 years, standard deviation: 18.4). Initial visual acuity was low (+1.07logMAR, standard deviation: 0.77); 5 eyes out of 15 had visual acuity +2logMAR or worse. Optic neuritis was mostly painful (8/9) and bilateral (6/9) but asymmetric. Optic disk swelling was reported in 9/15 eyes and 7/9 patients and was significantly associated with lower visual acuity in the acute phase (+1.46logMAR, standard deviation: 0.67 vs +0.5, standard deviation: 0.55; p = 0.03). After a mean observation period of 3.3 years (0.6–9.4 years, standard deviation: 3.4), median visual acuity was 0.05logMAR. All five patients were followed up for more than 1 year (5.4 years, standard deviation: 3.2) had 3–8 relapses (mean: 4.4, standard deviation: 2.1; annualized relapse rate: 1.2, standard deviation: 0.9). Final diagnosis was chronic relapsing idiopathic optic neuritis (n = 4), clinically isolated optic neuritis (n = 3), and neuromyelitis optica spectrum disorder aquaporin 4– (n = 2).

Conclusion:

Myelin oligodendrocyte glycoprotein+ optic neuritis has an atypical clinical presentation compared with multiple sclerosis and neuromyelitis optica spectrum disorder aquaporin 4+. Its evolution is closer to neuromyelitis optica spectrum disorder aquaporin 4+, with a better visual outcome.

Keywords

Aquaporin-4 antibodies (AQP4-IgG,NMO-IgG)Devic’s neuromyelitis optica myelin oligodendrocyte glycoprotein autoantibodies neuromyelitis optica spectrum disorder optic neuritis

Get full access to this article

View all access options for this article.

References

Ramanathan

Dale

Brilot

Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 2016; 15: 307–324.

Akaishi

Nakashima

Takeshita

et al . Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol 2016; 299: 152–157.

Ramanathan

Reddel

Henderson

et al . Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014; 1: e40.

Havla

Kümpfel

Schinner

et al . Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol 2017; 264: 139–151.

Sato

Callegaro

Lana-Peixoto

et al . Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474–481.

Jarius

Ruprecht

Kleiter

et al . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13: 280.

Petzold

Plant

GT.

Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2014; 261: 17–26.

Wingerchuk

Banwell

Bennett

et al . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189.

Höftberger

Sepulveda

Armangue

et al . Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015; 21: 866–874.

10.

The optic neuritis study group (ONTT). The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1991; 109: 1673–1678.

11.

Stiebel-Kalish

Lotan

Brody

et al . Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS One 2017; 12: e0170847.

12.

Beck

Cleary

Anderson

Jr et al . A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581–588.

13.

Elsone

Panicker

Mutch

et al . Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014; 20: 501–504.

14.

Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 2008; 115: 1079.e5–1082.e5.

15.

Garcia-Martin

Ara

Martin

et al . Retinal and optic nerve degeneration in patients with multiple sclerosis followed up for 5 years. Ophthalmology 2017; 124: 688–696.

16.

Beck

Gal

Bhatti

et al . Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004; 137: 77–83.

17.

Pache

Zimmermann

Mikolajczak

et al . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 2016; 13: 282.